Uncovering the Corona Virus Map Using Deep Entities and Relationship Models

We extract entities and relationships related to COVID-19 from a corpus of articles related to Corona virus by employing a novel entities and relationship model. The entity recognition and relationship discovery models are trained with a multi-task learning objective on a large annotated corpus. We employ a concept masking paradigm to prevent the evolution of neural networks functioning as an associative memory and induce right inductive bias guiding the network to make inference using only the context. We uncover several import subnetworks, highlight important terms and concepts and elucidate several treatment modalities employed in related ailments in the past.

[1]  Kyle Lo,et al.  The COVID-19 Open Research Dataset - Abstract , 2020, SIIRH@ECIR.

[2]  R. Albrecht,et al.  SARS-CoV-2 launches a unique transcriptional signature from in vitro, ex vivo, and in vivo systems , 2020, bioRxiv.

[3]  Leo Katz,et al.  A new status index derived from sociometric analysis , 1953 .

[4]  Kwok-Hung Chan,et al.  Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial , 2020, The Lancet.

[5]  E. Bouřa,et al.  Adenosine triphosphate analogs can efficiently inhibit the Zika virus RNA-dependent RNA polymerase. , 2017, Antiviral research.

[6]  S. Sriramula,et al.  Excessive Glutamate Stimulation Impairs ACE2 Activity Through ADAM17-Mediated Shedding in Cultured Cortical Neurons , 2018, Cellular and Molecular Neurobiology.

[7]  D. Smee,et al.  The Synthetic Antiviral Drug Arbidol Inhibits Globally Prevalent Pathogenic Viruses , 2016, Journal of Virology.

[8]  H. Naim,et al.  Polymorphisms in dipeptidyl peptidase 4 reduce host cell entry of Middle East respiratory syndrome coronavirus , 2020, Emerging microbes & infections.

[9]  Benjamin J. Polacco,et al.  A SARS-CoV-2 Protein Interaction Map Reveals Targets for Drug-Repurposing , 2020, Nature.

[10]  S. Shalhoub Interferon beta-1b for COVID-19 , 2020, The Lancet.

[11]  Z. Memish,et al.  Treatment of Middle East Respiratory Syndrome with a combination of lopinavir-ritonavir and interferon-β1b (MIRACLE trial): study protocol for a randomized controlled trial , 2018, Trials.

[12]  C. Rice,et al.  LY6E impairs coronavirus fusion and confers immune control of viral disease , 2020, Nature Microbiology.

[13]  Lukasz Kaiser,et al.  Attention is All you Need , 2017, NIPS.

[14]  H. Zeng,et al.  LY6E Restricts the Entry of Human Coronaviruses, including the currently pandemic SARS-CoV-2 , 2020, bioRxiv.

[15]  Yung-Hsien Chang,et al.  Design and biological activities of novel inhibitory peptides for SARS-CoV spike protein and angiotensin-converting enzyme 2 interaction , 2005, Antiviral Research.

[16]  Oren Etzioni,et al.  CORD-19: The Covid-19 Open Research Dataset , 2020, NLPCOVID19.

[17]  Tin-Yun Ho,et al.  Emodin blocks the SARS coronavirus spike protein and angiotensin-converting enzyme 2 interaction , 2006, Antiviral Research.